Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

eFFECTOR Therapeutics, Inc. - Common Stock (NQ: EFTR )

0.1800 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1800
Bid (Size) 0.1400 (3)
Ask (Size) 0.1550 (11)
Prev. Close 0.1800
Today's Range 0.1800 - 0.1800
52wk Range 0.1800 - 17.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off
Explore bankruptcy risk stocks with insights on Chicken Soup for the Soul Entertainment, eFFECTOR Therapeutics, and Delta Apparel. 
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace

Performance

YTD
-98.53%
-98.53%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
-36.40%
-36.40%
1 Year
-98.33%
-98.33%

More News

Read More
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why eFFECTOR Therapeutics (EFTR) Shares Are Down Over 70%
Via Benzinga
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
EFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dow Dips Over 200 Points; RPM International Shares Fall After Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Surges 1%; ConAgra Brands Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Via Benzinga
Dow Jumps Over 100 Points; US Jobless Claims Increase To 221,000
Via Benzinga
Topics Stocks
Exposures US Equities
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.